ELO_CountOn_Logo-01

Bleed protection*

for whatever
drives them

INDICATION: ELOCTATE is a recombinant DNA derived, antihemophilic factor indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Limitation of Use

ELOCTATE is not indicated for the treatment of von Willebrand disease.

Interested in ELOCTATE
for your patients?
REQUEST A REPRESENTATIVE
Interested in ELOCTATE for your patients?
REQUEST A REPRESENTATIVE

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.²

#1 prescribed based on HTC-reported data as of October 2021.1

See how ELOCTATE protects
EXPLORE BLEED AND
JOINT BLEED DATA
Discover the ELOCTATE MOE
SEE Fc FUSION IN ACTION
Looking for dosing information?
CALCULATE YOUR
PATIENT'S DOSE
Sanofi Logo

This site is intended for United States Residents only.

© 2022 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi are registered trademarks of Sanofi or an affiliate. MyELOCTATE is owned by Genzyme Corporation.
All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi.

MAT-US-2003073-v5.0-04/2022 Last Updated: April 2022